WallStSmart

Enbridge Inc (ENB)vsIDEXX Laboratories Inc (IDXX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Enbridge Inc generates 1415% more annual revenue ($65.19B vs $4.30B). IDXX leads profitability with a 24.6% profit margin vs 11.5%. ENB appears more attractively valued with a PEG of 1.82. ENB earns a higher WallStSmart Score of 67/100 (B-).

ENB

Strong Buy

67

out of 100

Grade: B-

Growth: 5.3Profit: 6.5Value: 10.0Quality: 4.5
Piotroski: 3/9Altman Z: 0.61

IDXX

Buy

61

out of 100

Grade: C+

Growth: 6.7Profit: 9.5Value: 4.7Quality: 5.0
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENBUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$109.98

Current Price

$54.48

$55.50 discount

UndervaluedFair: $109.98Overvalued
IDXXSignificantly Overvalued (-40.2%)

Margin of Safety

-40.2%

Fair Value

$462.85

Current Price

$575.72

$112.87 premium

UndervaluedFair: $462.85Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENB3 strengths · Avg: 9.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Market CapQuality
$116.68B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

IDXX3 strengths · Avg: 9.0/10
Return on EquityProfitability
66.2%10/10

Every $100 of equity generates 66 in profit

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

Areas to Watch

ENB4 concerns · Avg: 3.3/10
PEG RatioValuation
1.824/10

Expensive relative to growth rate

EPS GrowthGrowth
2.9%4/10

2.9% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
0.612/10

Distress zone — elevated risk

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
3.972/10

Expensive relative to growth rate

P/E RatioValuation
43.7x2/10

Premium valuation, high expectations priced in

Price/BookValuation
28.6x2/10

Trading at 28.6x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ENB

The strongest argument for ENB centers on Debt/Equity, Market Cap, Price/Book.

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.

Bear Case : ENB

The primary concerns for ENB are PEG Ratio, EPS Growth, Piotroski F-Score.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 43.7x leaves little room for execution misses.

Key Dynamics to Monitor

ENB profiles as a value stock while IDXX is a mature play — different risk/reward profiles.

IDXX carries more volatility with a beta of 1.70 — expect wider price swings.

IDXX is growing revenue faster at 14.3% — sustainability is the question.

IDXX generates stronger free cash flow (323M), providing more financial flexibility.

Bottom Line

ENB scores higher overall (67/100 vs 61/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enbridge Inc

ENERGY · OIL & GAS MIDSTREAM · USA

Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Want to dig deeper into these stocks?